Clinical trial of Mirazid in treatment of human fascioliasis, Ezbet El-Bakly (Tamyia Center) Al-Fayoum Governorate.

A field survey was done in Ezbet El-Bakly, Al-Fayoum Governorate, Egypt to assess the efficacy and safety of Mirazid in the treatment of human fascioliasis. Among 1019 individuals examined for parasitosis, the prevalence of fascioliasis was 1.7% and the geometric mean egg count (GMEC) was 33.2 eggs/gram stools. About 23.5% of the fascioliasis patients were asymptomatic. The most frequent symptoms were abdominal dis\tension and flatulence (76.5%), right hypochondrial pain (17.6%) and epigastric pain (17.6%). The most prevalent signs were pallor (52.9%,), tender right hypochondrium (23.5%) and tinge of jaundice (17.6%). All cases were treated by Mirazid as two capsules (600 mg) on an empty stomach an hour before breakfast for six consecutive days and followed up clinically and parasitologically. The parasitological cure rate, two and three months after treatment was 88.2% and 94.1% with an overt clinical cure without any side-effects. The cases not completely responding to a single course of treatment showed a marked reduction of the egg intensity. It was concluded that Mirazid (or Myrrh extract of Commiphora molmol) is safe and effective in the treatment of human fascioliasis under the field conditions.